Printer Friendly

BETH ISRAEL HOSPITAL: NEW OPTIONS FOR CHRONIC NON-HEALING WOUNDS

    BETH ISRAEL HOSPITAL:  NEW OPTIONS FOR CHRONIC NON-HEALING WOUNDS
    NEW YORK, Feb. 3 /PRNewswire/ -- Enormous strides are being made in the treatment of chronic non-healing wounds.  A multi-tiered treatment program at Beth Israel Hospital North in Manhattan has proven especially effective for diabetics and those suffering from peripheral vascular disease, steroid trophic ulceration, collagen vascular disease and venous stasis ulceration.
    Approximately 11 million people in the United States are diabetic, including 2 million who will suffer from a wound that won't heal in their lifetime.  Twenty percent of these patients are hospitalized for foot problems alone.  Unsuccessfully treated, many of these patients require foot amputation.  Even more disconcerting, only 33 percent of diabetics are alive three years after their amputations.
    At the Wound Healing Center, treatment requires that patients meet a rigorous protocol (which includes being a non-smoker and a moderate drinker) and take an active role in the daily care of the wound.  The bulk of this care is performed on an outpatient basis, eliminating lengthy hospital stays and possible complications associated with other treatment methods.  A recent study confirmed a healing rate of approximately 8.5 weeks.  This figure is heartening, as most patients who come to the would healing center have had no success with other treatments.
    The Treatment
    The first treatment step is to initiate a specific wound care protocol.  This includes cleansing the wound three times a day using an antibacterial soap and applying topical antibiotics and topical antifungal solutions to the wound.  Cultures are taken and if needed, the patient is treated with antibiotics.
    A vascular assessment is then performed to make sure the patient has adequate blood inflow.  A general medical evaluation is performed as needed, and nutritional, physical exam and podiatry consultations are available.
    Once the underlying causes of the would are clarified, the patient may undergo a surgical debridgement, or cleansing of the wound, to eradicate all of the infected tissue surrounding the wound.
    The patient is then treated with a specific adjuvant wound healing protocol to stimulate the growth of new tissue.  One of the more commonly used modalities is platelet-derived wound healing factor, made from the patient's own blood.  Each patient's medication is prepared on- site, at Beth Israel Hospital North in a special laboratory created for this purpose.  Platelet factors are used in conjunction with a comprehensive, multi-tiered treatment program.
    About Platelet-derived Wound Healing Factors
    When a platelet goes into a wound, it degranulates, emptying the contents of its granules into the are of the wound.  Within those granules are at lease five locally active factors, each of which has a role in either stimulating new tissue growth or in recruiting other cells from the blood to move in the wound and serve in infection control or regulation of the wound healing process.  In short, the platelet factors are stimulants for the deposition of collagen, new blood vessel development and new skin growth.
    The Wound Healing Center at Beth Israel Hospital North is a multi- disciplinary program which emphasizes high quality clinical care, research and teaching.  The only program of its kind in New York City, it is directed by Anthony C. Antonacci, M.D., a surgeon who specializes in wound healing.  Antonacci will deliver a free lecture for the community on "A New Approach to Wound Healing," Wednesday, Feb. 26, 1992 from, 7 to 8 p.m., at Beth Israel Hospital North.  To register, call 212-420-4247.
    Beth Israel Hospital North, a 229-bed, acute care hospital, is a member of the Beth Israel Health Care System.  That system also includes:  Beth Israel Medical Center, a 966-bed, tertiary care, teaching facility; the Phillips Beth Israel School of Nursing; the Beth Israel Nursing Home in White Plains, N.Y., and New York HealthCare, an ambulatory care facility in midtown Manhattan.
    -0-        2/3/92
    /CONTACT:  Bernadette Kelleher of Beth Israel Hospital North, 212-870-9550/ CO:  Beth Israel Hospital North ST:  New York IN:  HEA SU: SM-CK -- NY084 -- 6325 02/03/92 16:26 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 3, 1992
Words:663
Previous Article:AMGEN REPORTS FISCAL YEAR 1991 RESULTS
Next Article:AMERICAN MINING CONGRESS TO HOST ANNUAL MEMBERS MEETING FEB. 10
Topics:


Related Articles
PATIENTS PARTICIPATE IN NEW GRAND ROUNDS CONFERENCES AT BOSTON'S BETH ISRAEL HOSPITAL
CURATIVE HEALTH SERVICES TO PRESENT AT HAMBRECHT & QUIST HEALTH CARE CONFERENCE
BETH ISRAEL HOSPITAL AND YOUVILLE LIFECARE AGREE TO AFFILIATION
BETH ISRAEL AND DEACONESS TAKE MAJOR STEP TOWARDS MERGER
Agennix Inc. Receives $850,000 NIH Funding to Support Clinical Trials of rhLF Gel for Treatment of Patients with Diabetic Foot Ulcers.
Biofisica(TM) Receives European Clearance to Market First Bio-Electric Wound Care Dressing.
Celleration, Inc. Announces the Publication of a Clinical Study: Evaluation of the Effectiveness of MIST Ultrasound Therapy for the Healing of...
EnzySurge, Maker of DermaStream(TM), Establishes a US Office in the Virginia Biotech Commercialization Center.
Harrington Hospital readies MRI building, new services.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters